Pulse Biosciences (PLSE) Stock Jumps 17% After $13M Insider Buy

TLDR

• Pulse Biosciences (PLSE) stock rose 16.8% Tuesday after two top executives bought $13.3 million worth of stock.
• Co-Chairman Robert Duggan purchased 660,233 shares for ~$13 million, while CEO Paul LaViolette bought 15,000 shares for ~$295,000.
• The purchases were made through the company’s at-the-market (ATM) equity offering program during a designated trading window.
• PLSE develops nPulse nanosecond pulsed field ablation technology targeting atrial fibrillation treatments.
• The stock is up nearly 39% year-to-date, with a current market cap of $1.3 billion.

Pulse Biosciences (PLSE) stock jumped 16.8% on Tuesday after the company disclosed that two senior executives bought a combined $13.3 million in stock.

Pulse Biosciences, Inc., PLSE

Co-Chairman Robert Duggan and CEO Paul LaViolette made the purchases on May 11, 2026, during the company’s designated trading window.

The stock was trading up around 13% at the time of writing, bringing its year-to-date gain to roughly 39%.

Duggan led the buying, picking up 660,233 shares for approximately $13 million. LaViolette added 15,000 shares worth around $295,350.

Together, the two executives acquired 675,233 shares through Pulse Biosciences’ at-the-market equity program.

The ATM program lets the company sell stock directly into the open market. Using it to buy rather than sell sends a clear message to investors about internal confidence.

Why the Insider Activity Stands Out

Insider purchases at this scale are rare. A combined $13.3 million buy from two of the company’s top figures is the kind of move the market tends to notice — and react to.

It comes shortly after the company reported Q1 results and released new data on its nPulse catheter.

Analyst sentiment following those results was mixed. There was optimism around strong clinical outcomes in Europe and faster timelines for U.S. pivotal trials. But concerns remain around minimal revenue, widening losses, and elevated cash burn.

Pulse Biosciences carries a current market cap of $1.3 billion despite limited commercial revenue.

What PLSE Actually Does

The company’s core technology uses nanosecond pulsed field ablation — delivering ultra-short bursts of electrical energy to target cells while leaving surrounding tissue intact.

The primary focus is atrial fibrillation, a common heart rhythm disorder.

The company has been pushing to accelerate its U.S. regulatory timeline, with European feasibility data being cited as a positive signal by analysts.

Its average daily trading volume sits around 294,600 shares. Technical indicators currently show a “Strong Buy” signal.

TipRanks’ AI model rates PLSE as Neutral overall, pointing to weak financials offset by a solid balance sheet and the clinical pipeline progress.

The stock’s year-to-date gain of nearly 39% puts it well ahead of the broader market heading into the second half of 2026.

The post Pulse Biosciences (PLSE) Stock Jumps 17% After $13M Insider Buy appeared first on CoinCentral.